Frutarom has announced a new satiety and obesity study using its FenuLife galactomannan ingredient and has revealed positive results.
The company said that the study revealed an increase (P<0.05) in measurements of satiety and fullness, with reduced ratings of hunger and prospective food consumption at 8g. The researchers concluded that 8g dosage may have short-term beneficial effects in obese subjects.
According to the company, FenuLife is a naturally sourced, galactomannan ingredient manufactured from deodorised fenugreek and contains more than 75% soluble fiber.
The company claims that because of the molecular structure, FenuLife resists enzymatic degradation in the digestive system, maintaining its therapeutic properties. FenuLife has been proven in previous clinical trials to improve blood glucose response.
Jocelyn Mathern, the study’s principal investigator and the technical manager for Frutarom Health US, said: “FenuLife can be an effective ingredient in weight management formulations. Scientific literature points to many benefits of dietary fiber for weight management and this study has shown that FenuLife can have a significant positive effect in increasing feelings of fullness and reducing hunger.”
David Hart, manager of product at Frutarom, said: “These promising study results help position FenuLife as an innovative ingredient for weight management. This study is part of Frutarom’s ongoing commitment to support our product portfolio with proprietary science. In recent months, four additional clinical trials using our LifeLine ingredients have been completed or published.”
Frutarom operates through two divisions which includes the flavors division, which develops, produces and markets flavor compounds and food systems and fine ingredients division, which develops, produces and markets natural flavor extracts, functional food ingredients, natural pharmaceutical/nutraceutical extracts, specialty essential oils, citrus products and aroma chemicals.